Statistical analysis plan of the study titled "A deprescribing programme aimed to optimize blood glucose-lowering medication in older people with type 2 diabetes mellitus - the OMED2 study: a randomized controlled trial"

  • Charlotte Andriessen
  • , Peter P Harms
  • , Marieke T Blom
  • , Anna W de Boer
  • , G Ardine de Wit
  • , Ron Herings
  • , Rob J van Marum
  • , Jacqueline G Hugtenburg
  • , Daniël van Raalte
  • , Liselotte van Bloemendaal
  • , Giel Nijpels
  • , Rimke C Vos
  • , Petra Denig
  • , Petra J M Elders

Research output: Contribution to JournalArticleAcademicpeer-review

Abstract

BACKGROUND: The OMED2 (Optimization of Medication in Elderly with Diabetes) study addresses the effect and implementation of integrating a deprescribing programme (DPP) in general practice. The aim of the DPP is to reduce glucose-lowering medication (SU/insulin) in overtreated older patients. The protocol for this study has been published previously. This statistical analysis plan (SAP) contains a more elaborate outline of the (statistical) methods we plan to use for data analysis.

METHODS: The OMED2 study is a randomized mixed-methods study with a 2-year follow-up period that compares the effect of the implementation of a DPP in general practice to regular care (control). In this SAP, we report on the (statistical) approaches that we plan to use to address the study objectives. The main objective of the OMED2 study is to examine the effect of the implementation of the DPP on diabetes complications, whereby the total number of diabetes complications related to undertreatment and overtreatment will be summed. Generalized linear mixed models with a Poisson distribution and the DPP as the main determinant will be used to test whether the total number of diabetes complications occurring from the start of the 2-year follow-up until the end of follow-up differs between intervention and control. The incident rate of the number of diabetes complications will be calculated to correct for possible differences in follow-up duration. The model will also include a random effect variable to allow for possible clustering effects by general practice. We will perform intention-to-treat analyses, which include all patients eligible for deprescribing, as well as per protocol analyses, which omit patients who were not deprescribed in the intervention arm. Additionally, approaches to study the implementation of the DPP and the cost-effectiveness of the implementation are outlined in the SAP.

TRIAL REGISTRATION: ISRCTN Registry ISRCTN50008265. Registered on 1 November 2024.

Original languageEnglish
Article number171
JournalTrials
Volume27
Issue number1
DOIs
Publication statusE-pub ahead of print - 30 Jan 2026

Bibliographical note

© 2026. The Author(s).

Funding

The OMED2 study was funded by the Rational Pharmacotherapy Grant from ZonMW.

Funders
ZonMw

    Fingerprint

    Dive into the research topics of 'Statistical analysis plan of the study titled "A deprescribing programme aimed to optimize blood glucose-lowering medication in older people with type 2 diabetes mellitus - the OMED2 study: a randomized controlled trial"'. Together they form a unique fingerprint.

    Cite this